Background: Recently, serum beta2-microglobulin, an endogenous marker for renal function, has been shown to be an independent predictor of mortality in older adults. However, the prognostic role of beta2-microglobulin in heart failure has not been elucidated. Methods: We prospectively evaluated serum beta2-microglobulin and creatinine concentrations, creatinine-based renal parameters (estimated glomerular filtration rate and creatinine clearance), and echocardiographic data in 131 patients with acute heart failure and creatinine concentrations ≤3.0 mg/dL admitted to our hospitals. Results: During 2.3 ± 1.3 years, 42 patients died of cardiovascular causes and 12 died of noncardiac causes. Cardiovascular events were observed in 63 patients: 53 were readmitted due to worsening heart failure, 5 readmitted for cerebral embolism, and 5 died from sudden cardiac death. According to multivariate stepwise Cox proportional hazard analysis, higher baseline serum beta2-microglobulin concentrations (X 2 = 16, p < 0.0001), previous congestive heart failure (X 2 = 11, p < 0.001), presence of chronic obstructive pulmonary disease (X 2 = 8, p < 0.01), and lower diastolic blood pressure (X 2 = 6, p < 0.05) were independent predictors of increased cardiovascular events. Also, higher baseline serum beta2-microglobulin (X 2 = 20, p < 0.0001), lower systolic blood pressure (X 2 = 11, p < 0. (X 2 = 6, p < 0.05), and lower body mass index (X 2 = 5, p < 0.05) were independent predictors of increased cardiac mortality. The adjusted hazard ratio for cardiovascular events increased with baseline serum beta2-microglobulin above 2.1 mg/L: 2.9 with beta2-microglobulin of 2.2-2.6 mg/L (95%CI 1.2-6.9, p < 0.05), 2.9 with beta2-microglobulin of 2.7-3.9 mg/L (95%CI 1.2-7.2, p < 0.05), and 4.7 with beta2-microglobulin of ≥4.0 mg/L (95%CI 2.0-11, p < 0.001). Conclusions: Higher baseline serum beta2-microglobulin concentration could be a promising risk marker in acute heart failure patients with creatinine ≤3.0 mg/dL.
Introduction
Recent studies have underscored the importance of renal function parameters, namely estimated glomerular filtration rate (eGFR) [1, 2] , creatinine clearance [3, 4] , and cystatin-C [5] [6] [7] , as strong predictors of mortality and cardiac events in heart failure. Plasma levels of two low molecular weight proteins, cystatin-C and beta2-microglobulin, are indicators of GFR [8, 9] . A recent study [10] showed serum beta2-microglobulin to be an independent predictor of total mortality in a general population of older adults, and a better predictor than cystatin-C. However, the prognostic role of serum beta2-microglobulin in patients with heart failure has not been elucidated.
In this prospective study, we evaluated serum beta2-microglobulin as a predictor for long-term outcome in acute heart failure. We also compared the ability of beta2-microglobulin to determine risk in acute heart failure patients with creatinine-based renal parameters.
Methods

Study patients
Between January 2000 and January 2005, 131 consecutive congestive heart failure patients (77 ± 11 years of age) admitted to Kasai City Hospital or Kanzaki General Municipal Hospital, or followed up in the outpatient clinics, were examined. Among the 131 patients, 7 who rejected admission [New York Heart Association (NYHA) functional class II/III: 3/4] were recruited in outpatient clinics. The study was approved by the appropriate institutional review board, and all patients provided informed consent.
Congestive heart failure was confirmed according to Framingham criteria [11] , which include nocturnal dyspnea, orthopnea, dyspnea on exertion, edema, and pulmonary rales due to pulmonary congestion confirmed by chest radiography. We excluded patients with acute coronary syndrome, right ventricular failure, critical aortic or mitral stenosis, and severe renal dysfunction (i.e. plasma creatinine concentration >3.0 mg/dL) [1] . Patients with plasma B-type natriuretic peptide (BNP) concentrations <50 pg/mL were excluded due to a low probability of acute heart failure [12, 13] . Hypertension, ischemic heart disease, diabetes, and chronic obstructive pulmonary disease (COPD) were defined as previously described [13] . In the present study, 4 patients had previously undergone surgery for cancer, and 7 had concurrent malignancies (total 11 patients: 3 with stomach cancer, 1 with colon cancer, 1 lung cancer, 1 malignant lymphoma, and others), and 1 patient had rheumatoid arthritis.
Echocardiograph study
Baseline echocardiography was performed on each of all 131 patients using a Toshiba Sonolayer SSH 160A or SSA 350A (Toshiba Medical, Tokyo, Japan) or Hitachi ultrasound scanner EUB 6000 (Hitachi Medical, Tokyo, Japan). Left ventricular (LV) end-diastolic dimension, the diastolic thickness of the ventricular septum and the posterior LV wall, LV mass index, and relative LV wall thickness [(septal thickness + posterior LV wall thickness)/LV end-diastolic dimension] were determined as previously described [14, 15] . In patients with sinus rhythm, earlyto-atrial transmitral peak velocity ratio was measured as previously described [16] . The systolic pressure gradient between the right atrium and right ventricle, which presumes systolic pulmonary arterial pressure, was calculated from the velocity of tricuspid regurgitation. Pulmonary hypertension was defined as a ≥30 mm Hg systolic pressure gradient between the right atrium and ventricle. LV ejection fraction (EF) was determined by Teichholz's formula in patients without significant regional wall motion abnormalities. In patients with regional wall motion abnormalities, we assessed LVEF with the modified Simpson's rule [17] or by visual estimation [18] .
Laboratory measurements
Plasma BNP concentration was run fresh and determined by an immunoradiometric assay using an antibody to human BNP (Shionogi, Osaka, Japan) [19] . We measured serum blood urea nitrogen and creatinine (the enzyme method) concentration with routine commercial enzyme assay kits. We used a latex agglutination photometric immunoassay to determine serum concentrations of beta2-microglobulin (normal range 1.0-1.9 mg/L, Eiken Chemicals, Tokyo, Japan). We estimated GFR (mL/min/1.73 m 2 ) with the abbreviated modification of diet in renal disease (MDRD) equation modified by a Japanese coefficient [20] We obtained all of the data for each patient on the same day (n = 131). For 104/131 (79%) patients, the laboratory measurements were obtained within 3 days of echocardiography. Also, for 98/124 (79%) hospitalized patients, the laboratory measurements were taken within the 3rd hospital day. The laboratory data from the remaining 26 patients were taken at the median 5th (4-16th) hospital day.
Endpoints and follow-up
The endpoints were (1) cardiovascular events, defined as sudden cardiac death and hospital admission due to heart failure or cardiovascular complications, and (2) cardiac death, defined as death from cardiovascular causes.
Patients were prospectively followed up for an average of 2.3 ± 1.3 years. For 94/131 (72%) patients, a second set of echocardiography and laboratory measurements was obtained an average of 7 ± 7 weeks after treatment (Fig. 1) .
Statistical analysis
We compared data from heart failure patients with cardiac events to event-free patients during follow-up. Group averages are expressed as means ± standard deviation (SD), unless otherwise specified. BNP concentration was not normally distributed, and is expressed as median and interquartile range. Group comparisons of BNP values were performed with non-parametric tests. p-Values < 0.05 were considered significant. The associations of the variables with cardiac events or mortality were determined with a Cox proportional hazard analysis. Only variables with a pvalue < 0.05 in the univariate Cox analysis were included in a multivariate stepwise Cox analysis. Forward stepwise selection manner, with both values for inclusion and elimination set at p = 0.05, was used to create a final reduced model for predicting outcomes. For cardiac events, 20 significant variables were entered into the multivariate analysis: baseline variables (age, diastolic blood pressure, blood urea nitrogen, creatinine, beta2-microglobulin, eGFR, creatinine clearance, ischemic heart disease, previous myocardial infarction, previous congestive heart failure, COPD, and cancer) and post-treatment variables (NYHA class, pulmonary hypertension, BNP, blood urea nitrogen, creatinine, beta2-microglobulin, eGFR, and creatinine clearance). The proportional hazards assumption was checked with a log minus log plot.
The association of each variable with baseline serum beta2-microglobulin concentration was evaluated with a univariate linear regression analysis. Variables with a pvalue < 0.05 were entered into a multivariate stepwise regression.
We evaluated the association of quartiles of renal parameters as predictors of cardiac events. We determined the unadjusted and multivariate-adjusted risk for quartiles 2 through 4 compared with quartile 1. Adjusted cardiac eventfree survival curves were constructed for the quartiles of serum beta2-microglobulin after adjustment for all covariates. Data with missing data points were excluded from analysis. Data was analyzed using SPSS 11.0 software (SPSS, Chicago, IL, USA).
Results
Long-term outcome, baseline characteristics and post-treatment data in heart failure patients During the 2.3 ± 1.3 years after initiation of the study, cardiovascular events were observed in 63/131 (48%) patients: 53 (40%) patients were readmitted due to worsening heart failure, 5 (4%) readmitted for cerebral embolism, and 5 (4%) died from sudden cardiac death.
During follow-up, 54/131 (41%) patients died: 42 (32%) died of cardiovascular causes (33 from worsening heart failure, 2 from worsening cerebral embolism, and 7 from sudden cardiac death). Namely 2 patients died suddenly after discharge from hospital readmission due to worsening heart failure; 12 (9%) died of noncardiac causes (7 from cancer, 4 from pneumonia, and 1 phlegmon) (Fig. 1) .
Comparisons of the baseline characteristics of patients with cardiac events and event-free patients are presented in Table 1 . Baseline characteristics associated with cardiac events were advanced age, lower diastolic blood pressure, reduced body surface area, higher blood urea nitrogen, creatinine, and beta2-microglobulin, lower eGFR and creatinine clearance, ischemic heart disease, previous myocardial infarction, previous congestive heart failure, and less use of vasodilators at baseline.
After treatment, the NYHA functional class (I/II/III/IV post-treatment: 1/47/1/1 in event-free patients and 2/35/7/0 in patients with cardiac events) and BNP concentration [median (25th, 75th percentiles) post-treatment: 200 (80, 284) pg/mL in event-free patients and 255 (155, 498) pg/mL in patients with cardiac events] decreased in both groups of patients (p < 0.0001). Serum beta2-microglobulin concentration increased (p < 0.05) in both groups (2.9 ± 1.4 mg/L in event-free patients and 4.4 ± 2.3 mg/L in patients with cardiac events).
Predictors for long-term outcome
All the variables listed in Table 1 at baseline and after treatment were analyzed using univariate Cox proportional hazard analysis. Among the variables, 20 (see Methods section) and 19 (not shown) were significant predictors of cardiac events and cardiac mortality, respectively.
As shown in Table 2 , at baseline, serum beta2-microglobulin concentration was the most powerful predictor of cardiac events and cardiac mortality, as expressed by a chi-square value. A 1.58 mg/L (1 SD) increase in serum beta2-microglobulin was associated with a 1.5-fold increased risk of cardiac events. Previous congestive heart failure, presence of COPD and lower diastolic blood pressure were also independently associated with an increased risk of cardiac events. Likewise, lower systolic blood pressure, higher relative LV wall thickness, and lower body mass index were also independently associated with an increased risk of cardiac mortality.
In several types of malignancies [21, 22] , it was reported that adverse prognosis is associated with higher serum beta2-microglobulin concentration. Even if 11 patients with previous or concurrent malignancies were excluded from the analysis, serum beta2-microglobulin was still a strong and independent predictor of cardiac events and cardiac mortality (middle section of Table 2 ). In the multivariate Cox analysis including both baseline and post-treatment variables, baseline serum beta2-microglobulin was again a strong predictor of outcome (bottom section in Table 2 ). Higher BNP concentration post-treatment also independently contributed to increased cardiac mortality.
Variables associated with baseline serum beta2-microglobulin concentration
Elevated serum beta2-microglobulin has been reported in patients with a variety of non-renal illnesses, including solid malignancies, leukemia, and rheumatic diseases [23, 24] . To clarify the effects on serum beta2-microglobulin, all the parameters listed in Table 1 were evaluated by linear regression (Table 3 ). According to a multivariate stepwise linear regression analysis, age, sex, and serum creatinine were significant independent determinants of baseline serum beta2-microglobulin concentrations. According to the standardized coefficient, serum creatinine had a greater impact on serum beta2-microglobulin than age or sex. The square of the multivariate correlation coefficient (R 2 ) indicated that these three parameters accounted for 73% of serum beta2-microglobulin concentration.
Quartiles of renal parameters and cardiac-event risk
Next we compared the ability of beta2-microglobulin to distinguish cardiac-event risk with other renal parameters. As shown in Table 4 , after multivariate adjustment, the 4th quartile (≥4.0 mg/L) of baseline beta2-microglobulin was associated with a 4.7-fold increased cardiac-event risk compared to the 1st quartile (≤2.1 mg/L). Although the 4th quartiles of baseline creatinine and creatinine clearance were associated with a significantly greater adjusted event risk than the 1st quartile, besides the highest quartile, the 2nd and 3rd quartiles of beta2-microglobulin were also related to an increased risk for cardiac events. Adjusted cardiac event-free survival curves according to the quartile of beta2-microglobulin are shown in Fig. 2 .
Discussion
In the present study, we showed that a higher baseline concentration of serum beta2-microglobulin was the most powerful predictor of cardiac events and cardiac mortality in acute heart failure patients with creatinine ≤3.0 mg/dL. Furthermore, we demonstrated that baseline serum beta2-microglobulin concentration had a superior ability to distinguish cardiac-event risk in acute heart failure patients compared with creatinine-based renal parameters. The association of baseline concentration of serum beta2-microglobulin with cardiovascular events or cardiac mortality was still obtained when patients with cancer were excluded from analysis.
Risk factors for prognosis
In addition to beta2-microglobulin, several other risk factors for outcome were identified in this study (Table 2) . Prognostic values of previous heart failure [25] , COPD [26] , systolic [7, 27] and diastolic blood pressure [25] , and body mass index [5, 25, 27] in heart failure were confirmed previously. Posttreatment BNP levels [28, 29] also have been reported to be strong predictors of mortality in heart failure.
Serum beta2-microglobulin as a predictor of long-term outcome
Widely distributed in nucleated cells in the body and shed into the circulation, beta2-microglobulin is filtered Data are expressed as mean ± SD, number and/or percent of patients, or median (25th, 75th) percentiles. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; E/A, early-to-atrial transmitral peak velocity ratio; EDD, end-diastolic dimension; EF, ejection fraction; eGFR, estimated glomerular filtration rate; LV, left ventricular; NYHA, New York Heart Association; SBP, systolic blood pressure. a Data from patients with atrial fibrillation were excluded. b Median and (25th, 75th percentiles) are shown. c eGFR was calculated by the abbreviated modification of diet in renal disease (MDRD) equation modified by a Japanese coefficient; creatinine clearance was by the Cockroft-Gault equation (see Methods section).
d Patients who had previously undergone surgery for cancer (n = 4) or had concurrent malignancies (n = 7) at baseline. e Data of medication use after 7 ± 7 weeks from 94 patients for whom follow-up measurements were available. by glomeruli and reabsorbed by the proximal tubular cells where it is metabolized. Its plasma concentration increases with renal dysfunction, and may be a surrogate marker of GFR [8, 9, 24, 30] . Indeed, as shown in Table 3 , beta2-microglobulin concentration strongly correlated with eGFR and creatinine clearance, and was determined by creatinine, age, and sex, in accordance with previous studies [8, 9, 23] . Although eGFR and creatinine clearance values Figure 2 Adjusted cardiac event-free survival curves in acute heart failure patients according to baseline serum beta2-microglobulin concentrations. The data were adjusted for differences in baseline variables, including age, diastolic blood pressure, ischemic heart disease, previous congestive heart failure, chronic obstructive pulmonary disease, and cancer.
were also based on creatinine concentration, age, and sex (see Methods section), serum beta2-microglobulin was a better prognostic marker for acute heart failure patients than these creatinine-based measures (Table 4) .
First, recent reports [31, 32] showed that GFR could not be estimated accurately with the abbreviated MDRD or Cockroft-Gault equations in persons with normal serum creatinine concentrations, as the correlation between measured GFR and estimated GFR was weak (R 2 ≤ 0.40). The low body mass index observed in our patients (Table 1) suggested the possibility of malnourishment. Therefore, methods based on creatinine (mean 1.0 ± 0.4 mg/dL in the present study) may overestimate actual GFR, while serum beta2-microglobulin would not be affected by reduced muscle mass [8] .
Second, serum creatinine concentration, age, and sex accounted for 73% of serum beta2-microglobulin concentration (R 2 = 0.73, Table 3 ). Regarding the remaining 27% of beta2-microglobulin, several diseases, including malignancies and inflammatory diseases, show an increased production of beta2-microglobulin, resulting in increased serum concentration despite normal GFR [23, 24] . Of note, a recent study [10] demonstrated a significant (p < 0.001) association of serum beta2-microglobulin concentration with serum high-sensitivity C-reactive protein levels in a healthy, older cohort, suggesting that serum beta2-microglobulin reflects low-grade inflammation. Therefore, serum beta2-microglobulin concentration may also reflect factors other than renal function that are related to mortality.
Limitations
Although the prognostic value of beta2-microglobulin in this study was statistically highly significant, the number of patients was small. Further studies in a large number of patients are needed to confirm the prognostic role of serum beta2-microglobulin in acute heart failure.
Conclusions
Higher baseline serum beta2-microglobulin concentration could be a promising risk marker in acute heart failure patients with creatinine ≤3.0 mg/dL.
